Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment of pediatric Hyperphosphatemia.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
The financing will support the commercialization of company's two FDA approved products, Ibsrela (tenapanor), for irritable bowel syndrome with constipation, and Xphozah (tenapanor), indicated to reduce serum phosphorus in adults with chronic kidney disease.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SLR Capital Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 17, 2023
Details:
Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment in adult with chronic kidney disease on dialysis.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Phozevel (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the NHE3, indicated for the treatment improvement of hyperphosphatemia in adult patients with CKD on dialysis.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Phozevel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
The agreement provides Fosun Pharma the rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome with constipation and for the treatment of hyperphosphatemia related to chronic kidney disease.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: $125.0 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement July 13, 2023
Details:
Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment in adult with chronic kidney disease on dialysis.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment in adult with chronic kidney disease on dialysis.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Details:
XPHOZAH (tenapanor),is an investigational first-in-class phosphate absorption inhibitor, With its unique blocking MOA, XPHOZAH acts locally in gut, reducing phosphate absorption through paracellular pathway, primary pathway of phosphate absorption.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Under the terms of the agreement, Ardelyx will execute a research plan to advance two of Ardelyx’s ongoing research programs focused on the identification and design of Tenapanor (xphozah), a phosphate absorption inhibitor, for the treatment of Hyperphosphatemia.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: $520.5 million Upfront Cash: $10.5 million
Deal Type: Licensing Agreement October 31, 2022